AU6305096A - Azetidinone derivatives for the treatment of atherosclerosis - Google Patents
Azetidinone derivatives for the treatment of atherosclerosisInfo
- Publication number
- AU6305096A AU6305096A AU63050/96A AU6305096A AU6305096A AU 6305096 A AU6305096 A AU 6305096A AU 63050/96 A AU63050/96 A AU 63050/96A AU 6305096 A AU6305096 A AU 6305096A AU 6305096 A AU6305096 A AU 6305096A
- Authority
- AU
- Australia
- Prior art keywords
- atherosclerosis
- treatment
- azetidinone derivatives
- azetidinone
- derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
- C07D205/085—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a nitrogen atom directly attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
- C07D205/09—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4
- C07D205/095—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4 and with a nitrogen atom directly attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9513442 | 1995-07-01 | ||
| GBGB9513442.5A GB9513442D0 (en) | 1995-07-01 | 1995-07-01 | Novel compounds |
| GBGB9515056.1A GB9515056D0 (en) | 1995-07-22 | 1995-07-22 | Novel compounds |
| GB9515056 | 1995-07-22 | ||
| GBGB9515206.2A GB9515206D0 (en) | 1995-07-25 | 1995-07-25 | Novel compounds |
| GB9515206 | 1995-07-25 | ||
| GB9516985 | 1995-08-18 | ||
| GBGB9516985.0A GB9516985D0 (en) | 1995-08-18 | 1995-08-18 | Novel compounds |
| GB9525132 | 1995-12-08 | ||
| GBGB9525132.8A GB9525132D0 (en) | 1995-12-08 | 1995-12-08 | Novel compounds |
| GB9608650 | 1996-04-26 | ||
| GB9608651 | 1996-04-26 | ||
| GBGB9608651.7A GB9608651D0 (en) | 1996-04-26 | 1996-04-26 | Novel compounds |
| GBGB9608650.9A GB9608650D0 (en) | 1996-04-26 | 1996-04-26 | Novel compounds |
| PCT/EP1996/002765 WO1997002242A1 (en) | 1995-07-01 | 1996-06-20 | Azetidinone derivatives for the treatment of atherosclerosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU6305096A true AU6305096A (en) | 1997-02-05 |
| AU708032B2 AU708032B2 (en) | 1999-07-29 |
Family
ID=27562921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU63050/96A Ceased AU708032B2 (en) | 1995-07-01 | 1996-06-20 | Azetidinone derivatives for the treatment of atherosclerosis |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP0840725A1 (en) |
| JP (1) | JP2002515852A (en) |
| KR (1) | KR19990028630A (en) |
| CN (1) | CN1197452A (en) |
| AP (1) | AP728A (en) |
| AU (1) | AU708032B2 (en) |
| BG (1) | BG102214A (en) |
| BR (1) | BR9609445A (en) |
| CA (1) | CA2225627A1 (en) |
| CZ (1) | CZ422197A3 (en) |
| EA (1) | EA199800109A1 (en) |
| HU (1) | HUP9901153A3 (en) |
| IL (1) | IL122650A0 (en) |
| MA (1) | MA23922A1 (en) |
| MX (1) | MX9800186A (en) |
| NO (1) | NO976158L (en) |
| NZ (1) | NZ311684A (en) |
| OA (1) | OA10648A (en) |
| PE (1) | PE8998A1 (en) |
| PL (1) | PL324240A1 (en) |
| SK (1) | SK178497A3 (en) |
| TR (1) | TR199701762T1 (en) |
| WO (1) | WO1997002242A1 (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0869943A1 (en) * | 1995-12-08 | 1998-10-14 | Smithkline Beecham Plc | Monocyclic beta-lactame derivatives for treatment of atherosclerosis |
| HUP9901359A3 (en) * | 1996-04-26 | 2000-03-28 | Smithkline Beecham Plc | Azetidinone derivatives for the treatment of atherosclerosis, process for their producing and pharmaceutical compositions containing them |
| GB9608649D0 (en) * | 1996-04-26 | 1996-07-03 | Smithkline Beecham Plc | Novel compounds |
| CZ304450B6 (en) | 2000-02-16 | 2014-05-14 | Smithkline Beecham P. L. C. | Pyrimidine derivative |
| GB0024808D0 (en) | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
| BRPI0721697A2 (en) | 2007-05-11 | 2014-08-05 | Univ Jefferson | "METHODS FOR TREATING AND / OR PREVENTING NEURODEGENERATIVE DISEASE OR DISORDER IN AN INDIVIDUAL, TO TREAT AND / OR PREVENTING AN INDIVIDUAL WITH OR AT RISK OF VASCULAR DEMENTIA, TO TREAT AND / OR PREVENTING A BARRIERAL DISORDER OR DISORDER AN INDIVIDUAL, TO REDUCE BETA AMILOID ACCUMULATION IN THE BRAIN OF AN INDIVIDUAL, TO TREAT AND / OR PREVENT ALZHEIMER IN AN INDIVIDUAL AND TO PREVENT OR REDUCE THE RISK OF DEVELOPING ALZHHEIMER MISUSE, AND IN USE OF AND / OR LP-PLA2 PROTEIN ACTIVITY. " |
| AU2008251467B2 (en) | 2007-05-11 | 2014-07-31 | The Trustees Of The University Of Pennsylvania | Methods of treatment of skin ulcers |
| US8962633B2 (en) | 2007-05-11 | 2015-02-24 | Thomas Jefferson University | Methods of treatment and prevention of metabolic bone diseases and disorders |
| WO2012076435A1 (en) | 2010-12-06 | 2012-06-14 | Glaxo Group Limited | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp - pla2 |
| WO2012080497A2 (en) | 2010-12-17 | 2012-06-21 | Glaxo Group Limited | Methods of treatment and prevention of eye diseases |
| WO2013000267A1 (en) | 2011-06-27 | 2013-01-03 | 中国科学院上海药物研究所 | Azole heterocyclic compound, preparation method, pharmaceutical composition and use |
| TW201321382A (en) | 2011-07-27 | 2013-06-01 | Glaxo Group Ltd | Compounds |
| BR112014001665A2 (en) | 2011-07-27 | 2017-02-14 | Glaxo Group Ltd | 2,3-dihydroimidazo [1,2-c] pyrimidin-5 (1h) -one compounds used as lp-plaz inhibitors |
| BR112015017397A2 (en) | 2013-01-25 | 2017-07-11 | Glaxosmithkline Ip Dev Ltd | bicyclic pyrimidone compounds as lp-pla2 inhibitors |
| KR20150111356A (en) | 2013-01-25 | 2015-10-05 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Compounds |
| UY35276A (en) | 2013-01-25 | 2014-08-29 | Glaxosmithkline Ip Dev Ltd | New compounds that inhibit the activity of Lp-PLA2 |
| WO2016012917A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
| WO2016012916A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
| MX2022005615A (en) | 2019-11-09 | 2022-07-27 | Shanghai Simr Biotechnology Co Ltd | Tricyclic dihydroimidazopyrimidone derivative, preparation method therefor, pharmaceutical composition and use thereof. |
| CN115304620A (en) | 2021-05-07 | 2022-11-08 | 上海赛默罗生物科技有限公司 | Pyrimidone derivatives, preparation method, pharmaceutical composition and application thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4680391A (en) * | 1983-12-01 | 1987-07-14 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
| IL89835A0 (en) * | 1988-04-11 | 1989-12-15 | Merck & Co Inc | Substituted azetidinones,their preparation and pharmaceutical compositions containing them |
| IL99658A0 (en) * | 1990-10-15 | 1992-08-18 | Merck & Co Inc | Substituted azetidinones and pharmaceutical compositions containing them |
| GB9421816D0 (en) * | 1994-10-29 | 1994-12-14 | Smithkline Beecham Plc | Novel compounds |
| JPH11500415A (en) * | 1994-12-22 | 1999-01-12 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | Substituted azetidin-2-ones for treating atherosclerosis |
-
1996
- 1996-06-20 AP APAP/P/1997/001161A patent/AP728A/en active
- 1996-06-20 BR BR9609445A patent/BR9609445A/en unknown
- 1996-06-20 CZ CZ974221A patent/CZ422197A3/en unknown
- 1996-06-20 WO PCT/EP1996/002765 patent/WO1997002242A1/en not_active Application Discontinuation
- 1996-06-20 TR TR97/01762T patent/TR199701762T1/en unknown
- 1996-06-20 AU AU63050/96A patent/AU708032B2/en not_active Ceased
- 1996-06-20 IL IL12265096A patent/IL122650A0/en unknown
- 1996-06-20 HU HU9901153A patent/HUP9901153A3/en unknown
- 1996-06-20 SK SK1784-97A patent/SK178497A3/en unknown
- 1996-06-20 NZ NZ311684A patent/NZ311684A/en unknown
- 1996-06-20 PL PL96324240A patent/PL324240A1/en unknown
- 1996-06-20 EP EP96922030A patent/EP0840725A1/en not_active Withdrawn
- 1996-06-20 CN CN96196661A patent/CN1197452A/en active Pending
- 1996-06-20 CA CA002225627A patent/CA2225627A1/en not_active Abandoned
- 1996-06-20 EA EA199800109A patent/EA199800109A1/en unknown
- 1996-06-20 KR KR1019970709952A patent/KR19990028630A/en not_active Application Discontinuation
- 1996-06-20 JP JP50477297A patent/JP2002515852A/en active Pending
- 1996-06-28 PE PE1996000496A patent/PE8998A1/en not_active Application Discontinuation
- 1996-06-28 MA MA24298A patent/MA23922A1/en unknown
-
1997
- 1997-12-30 NO NO976158A patent/NO976158L/en unknown
- 1997-12-31 OA OA70172A patent/OA10648A/en unknown
-
1998
- 1998-01-07 MX MX9800186A patent/MX9800186A/en unknown
- 1998-01-28 BG BG102214A patent/BG102214A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE8998A1 (en) | 1998-03-20 |
| CA2225627A1 (en) | 1997-01-23 |
| MX9800186A (en) | 1998-07-31 |
| BG102214A (en) | 1998-08-31 |
| KR19990028630A (en) | 1999-04-15 |
| JP2002515852A (en) | 2002-05-28 |
| HUP9901153A3 (en) | 1999-11-29 |
| AU708032B2 (en) | 1999-07-29 |
| NO976158L (en) | 1998-02-25 |
| OA10648A (en) | 2002-09-25 |
| MA23922A1 (en) | 1996-12-31 |
| IL122650A0 (en) | 1998-08-16 |
| HUP9901153A2 (en) | 1999-08-30 |
| SK178497A3 (en) | 1998-07-08 |
| BR9609445A (en) | 1999-04-06 |
| TR199701762T1 (en) | 1998-05-21 |
| AP9701161A0 (en) | 1998-01-31 |
| EP0840725A1 (en) | 1998-05-13 |
| NZ311684A (en) | 2000-04-28 |
| WO1997002242A1 (en) | 1997-01-23 |
| EA199800109A1 (en) | 1998-10-29 |
| NO976158D0 (en) | 1997-12-30 |
| CN1197452A (en) | 1998-10-28 |
| AP728A (en) | 1999-01-29 |
| PL324240A1 (en) | 1998-05-11 |
| CZ422197A3 (en) | 1998-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU3869895A (en) | Azetidinone derivatives for the treatment of atherosclerosis | |
| AU4389896A (en) | Substituted azetidin-2-ones for treatment of atherosclerosis | |
| AU4665596A (en) | Pyrazolylbenzoyl derivatives | |
| AU7443496A (en) | Treatment of migraine | |
| AU6305096A (en) | Azetidinone derivatives for the treatment of atherosclerosis | |
| AU7626596A (en) | Oxymethoxy-3-aryl-pyrone derivatives | |
| AU1195897A (en) | Heteroarylcarboxamide derivatives | |
| AU4086296A (en) | Indolepiperidine derivatives | |
| AU7053296A (en) | Purin-6-one derivatives | |
| AU2698697A (en) | Azetidinone derivatives for the treatment of atherosclerosis | |
| AU4875296A (en) | Isoxazolyl-benzoyl derivatives | |
| AU5763596A (en) | 2-ureido-benzamide derivatives | |
| AU697028B2 (en) | N-acyl-2 aryl cycloalkylmethylamine derivatives as melatonergics | |
| AU6191796A (en) | Sulfonyl- or sulfinylbenzoylguanidine derivatives | |
| AU7084796A (en) | Diarylalkenylamine derivatives | |
| AU4547796A (en) | Hexahydropyrazinoquinoline derivatives | |
| AU5052296A (en) | 4-indolylpiperazinyl derivatives | |
| AU4877196A (en) | Derivatives of 3-pyrrolidylidene-2-one-cephalosporines | |
| AU4211296A (en) | 4-aminobenzoylguanidine derivatives | |
| AU6929696A (en) | Pyrazol-4-ylbenzoyl derivatives | |
| AU3473193A (en) | Treatment for atherosclerosis | |
| AU4547396A (en) | Thioquinoline derivatives | |
| AU4546096A (en) | Treatment of waste | |
| AU6829696A (en) | Treatment of solutions | |
| AU2611695A (en) | Sailboatsystem for controlled gibing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |